Oryzias melastigma (Indian medaka)
| UniProt ID | Protein Name | Gene Symbol | No. of Glycosylation Sites | No. of GlyTouCan IDs | Disease Ontology |
|---|---|---|---|---|---|
| A0A834BZV9 | Hyaluronidase |
|
1 | 0 |
|
| A0A3B3BEG8 | Cathepsin D-like |
|
2 | 0 |
|
| A0A3B3DF70 | Phosphoinositide phospholipase C |
|
2 | 0 |
|
| A0A3B3CXF8 | Hyaluronidase |
|
1 | 0 |
|
| A0A3B3BGN1 | Angiotensin-converting enzyme |
|
1 | 0 |
|
| A0A3B3BFZ8 | Angiotensin-converting enzyme |
|
2 | 0 |
|
| A0A3B3BLC2 | Rhodopsin |
|
2 | 0 |
|
| A0A834FEP9 | Voltage-dependent L-type calcium channel subunit alpha |
|
1 | 0 |
|
| A0A834C4K4 | Proto-oncogene tyrosine-protein kinase receptor Ret |
|
1 | 0 |
|
| A0A834BVX1 | Voltage-dependent L-type calcium channel subunit alpha |
|
1 | 0 |
|
| A0A3B3BIN4 | Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase |
|
1 | 0 |
|
| A0A3B3D6Z8 | Voltage-dependent L-type calcium channel subunit alpha |
|
1 | 0 |
|
| A0A834F110 | P2X purinoceptor |
|
1 | 0 |
|
| A0A834BW74 | Phosphoinositide phospholipase C |
|
1 | 0 |
|
| A0A3B3CQD7 | P2X purinoceptor |
|
1 | 0 |
|
| A0A3B3CGG0 | Fibroblast growth factor receptor |
|
8 | 0 |
|
| A0A3B3D5X5 | Voltage-dependent L-type calcium channel subunit alpha |
|
1 | 0 |
|
| A0A3B3DHW5 | Hyaluronidase |
|
1 | 0 |
|
| A0A834FQQ8 | Phosphoinositide phospholipase C |
|
1 | 0 |
|
| A0A3B3CUX5 | Pannexin |
|
1 | 0 |
|
| A0A834FJX6 | Voltage-dependent L-type calcium channel subunit alpha |
|
1 | 0 |
|
| A0A834EYB5 | Potassium channel subfamily K member |
|
1 | 0 |
|
| A0A834FGX6 | Voltage-dependent N-type calcium channel subunit alpha |
|
1 | 0 |
|
| A0A3B3B9V8 | P2X purinoceptor |
|
1 | 0 |
|
| A0A3B3CY59 | Protein adenylyltransferase FICD |
|
1 | 0 |
|
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
This work is licensed under Creative Commons Attribution 4.0 International
GlyCosmos Portal v4.5.0
Last updated: April 6, 2026